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Brain-derived neurotrophic factor increase during treatment
in severe mental illness inpatients
GL Nuernberg1, B Aguiar2, G Bristot2, MP Fleck1 and NS Rocha1
Meta-analytical evidence suggests that brain-derived neurotrophic factor (BDNF) is altered in various psychiatric disorders.
However, meta-analyses may be hampered by the heterogeneity of BDNF assays, lack of BDNF standard values and heterogeneity
among the populations included in the studies. To address these issues, our study aimed to test, in a ‘true-to-life’ setting, the
hypothesis that the serum BDNF level is nonspecifically reduced in acute severe mental illness (SMI) patients and increases during
inpatient treatment. Consecutive samples of 236 inpatients with SMI and 100 healthy controls were recruited. SMI includes
schizophrenia and severe mood disorders, and is characterized in the sample by the presence of at least 2 years of psychiatric
treatment and disability. Generalized estimating equations were used to analyze BDNF serum levels at admission and upon
discharge controlled by confounding factors. BDNF levels increased significantly between admission and discharge in SMI patients.
BDNF levels showed significant reductions compared with controls both at admission and upon discharge. In addition, BDNF levels
showed no difference among SMI patient diagnostic subgroups (unipolar depression, bipolar depression, schizophrenia and manic
episode). The increase but non-restoration of BDNF levels, even with the general acute improvement of clinical scores, may reflect
the progression of the disorder characteristically seen in these patients. BDNF levels could be considered as a marker for the
presence of a nonspecific psychiatric disorder and possibly a transdiagnostic and nonspecific marker of disease activity.
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INTRODUCTION
Severe mental illness (SMI) encompasses a wide range of
psychiatric disorders, including schizophrenia and severe mood
disorders.1 A suggested definition of SMI from the National
Institute of Mental Health2 is based on the following two criteria:
(1) duration, characterized as involving ‘prolonged illness’ and
‘long-term treatment’, operationalized as a ⩾ 2-year history of
mental illness or treatment and (2) disability, which includes
dangerous or disturbing social behavior, moderate impairment in
work and non-work activities, and mild impairment in basic
needs.3,4
Brain-derived neurotrophic factor (BDNF) is found throughout
the brain and is involved in neurogenesis and neuroplasticity,
having a potential role in the pathophysiology of many
neuropsychiatric disorders.5 Several studies have assessed BDNF
levels in various neuropsychiatric disorders (that is, major
depression,6,7 bipolar disorder8 and schizophrenia9,10), and
evidence suggests that BDNF levels are significantly decreased
in these disorders. A meta-analysis found no differences in the
decrease of peripheral BDNF levels among patients with mood
disorders (major depression, bipolar depression and manic episode)
and schizophrenia in acute states.11 In addition, decreased BDNF
levels were observed in mood disorders during acute episodes
when compared with those levels in euthymia/remission.11
Because most studies have shown a decrease in BDNF9,12 in
schizophrenia, BDNF can be considered a schizophrenia biomar-
ker, and may also have a role in the process of neuroprogression
in other neuropsychiatric disorders.13
However, meta-analyses may be hampered by the heteroge-
neity of BDNF assays, lack of BDNF standard values and
heterogeneity among the populations included in the studies.
To address these issues, our study aimed to test, in a ‘true-to-life’
setting, the hypothesis that the BDNF serum level nonspecifically
decreases in acute SMI patients and increases during inpatient
treatment. Until now, there have been few data available about
BDNF levels in single samples of patients with different diagnoses,
or in patients with SMI in acute clinical presentations.
The objectives of the present study were as follows:
● To evaluate SMI patients’ BDNF levels at admission and upon
discharge following inpatient treatment at a general hospital.
● To compare BDNF levels among different SMI patient diagnostic
subgroups (major depression, bipolar depression, manic epi-
sode and schizophrenia).
● To compare BDNF levels in SMI patients at both admission and
discharge with those of healthy controls.
MATERIALS AND METHODS
Patients were recruited in a general hospital, tertiary inpatient psychiatric
unit (Hospital de Clínicas de Porto Alegre, Brazil), and provided written
informed consent. Patients aged 18 years or older admitted between June
2011 and December 2013 were invited to participate. Exclusion criteria
included insufficient communication skills to participate in the interview or
provide written informed consent, and those patients with a primary
diagnosis of drug or alcohol dependence. The study was conducted in
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compliance with the Declaration of Helsinki and was approved by the local
ethics committee (GPPG-HCPA id: 100265).
Controls were recruited from a local blood donation center. The healthy
control group comprised 100 volunteers who were screened for psychiatric
disorders with the Self-Reporting Questionnaire - Brazilian version (SRQ-
-20).14 Those included in the study were not using any psychiatric
medication nor had any other general medical condition.
Upon admission to the inpatient unit, patients were screened for
eligibility. Patients were included if they had the two SMI criteria of having
any mental disorder, with Global Assessment of Functioning (GAF) ⩽ 50 (in
the initial evaluation) and duration of previous services contact ⩾ 2 years.3
Within 72 h of hospitalization, the following clinical evaluations were
undertaken: Mini-International Neuropsychiatric Interview (MINI);15 Clinical
Global Impression scale—Severity (CGI-S),16 a clinician-rated seven-point
scale that measures disease severity; Brief Psychiatric Rating Scale,17 to
measure psychiatric symptoms such as depression, anxiety, hallucinations
and unusual behavior; GAF,18 to measure symptomatology and function-
ing; Cumulative Illness Rating Scale (CIRS) to evaluate comorbidities.19
Clinical and sociodemographic assessments were performed by trained
psychiatrists and psychiatry residents. Blood samples were also obtained.
Patients were also evaluated 72 h before discharge from the unit, and
blood samples were also collected at this time.
BDNF assessments
Ten-milliliter samples of venous blood were collected into an
anticoagulant-free vacuum tube between 1300 hours and 1700 hours.
Blood was then centrifuged at 4000 g for 10 min and serum was collected
and stored at − 80 °C. Serum BDNF levels were measured by sandwich
enzyme-linked immunosorbent assay (ELISA) in accordance with the
manufacturer’s instructions (ChemiKine Brain Derived Neurotrophic Factor
Sandwich ELISA Kit, Catalogue No. CYT306, Millipore, Billerica, MA, USA).
Microtiter plates (96-well flat-bottom) were coated for 24 h at 4 °C with the
samples diluted 1:100 in sample diluent. The standard curve ranged from
7.8 to 500 pg ml− 1 of BDNF. Plates were then washed four times with wash
buffer and a biotinylation mouse anti-human BDNF monoclonal antibody
(diluted 1:1000 in sample diluent) was added, and incubated for 3 h.
After washing, a second incubation was performed with streptavidin-
horseradish peroxidase conjugate solution (diluted 1:1000) for 1 h. These
procedures were performed at room temperature. After addition of
substrate and stop solution, the amount of BDNF was determined
(absorbance set at 450 nm). The standard curve showed a direct
relationship between optical density and BDNF concentration. The assay
range of detection is 15–1000 pg ml− 1. The manufacturer reports no
significant crossreactivity with NGF, NT4/5 or NT3. In addition, intra-assay
and inter-assay coefficients of variation are +3.7% (250 pg ml− 1) and
+8.5% (250 pg ml− 1), respectively. Tests were not performed in duplicate
and the investigator was not blinded to the group allocation during the
experiment.
Statistical analysis
All analyses were performed using the Statistical Package for the Social
Sciences, version 18 software for Windows (SPSS, Chicago, IL, USA). The
normality of the data distribution was examined by the Shapiro–Wilk test.
The means were compared between groups using the Student’s t-test for
continuous variables, the Χ2-test for categorical variables or one-way
analysis of variance when appropriate, followed by the Tukey post hoc test
when statistical significance was reached.
Generalized estimating equations (GEEs) were used for longitudinal data
analysis. GEE can be used in models with non-normally distributed errors
and non-balanced data (that is, when there are missing data).20 In this
study, two GEEs were performed. The first analysis evaluated BDNF levels
at admission and upon discharge in SMI patients controlled by diagnostic
subgroup (major depression, bipolar depression, manic episode and
schizophrenia), age, sex, length of stay and weight. The second analysis
compared BDNF serum levels between SMI patients and controls at both
time points. As there was only one time point assessment in the control
group, BDNF values were repeated in the analysis. Age, sex, weight and the
presence of a severe systemic condition were also controlled. The
parameters chosen for GEE were as follows: identity link, robust estimator
(covariance matrix) and unstructured working correlation matrix. P-values
less than 0.05 were considered to indicate statistical significance.
The sample size was based on a previously published observational
study,21 whose subjects were recruited from the same site as ours. To
detect a mean difference of 0.5, with an alpha level of 0.05 (two-tailed) and
80% power, 17 in each group (patients and controls) is the required
sample size.
Table 1. Total sample sociodemographic, clinical and treatment characteristics (controls, severe mental illness patients and subgroups divided by
diagnosis)
Variables SMI n= 236 Controls
n= 100









Sex, F 134 (56.7) 44 8.4 0.004 74 (67.2) 14 (66.6) 27 (62.7) 19 (30.6) 25.40 o0.001 (Ma= Bd=Md)4Sz
Age, years 44.8 (14.1) 33.6 (10.9) 17.0 o0.001 47.8 (13.6) 49.3 (11.8) 42.0 (17.1) 40.9 (12.0) 4.33 0.005 (Md4Sz)=Ma=Bd
Years of study 9.7 (4.5) 12.3 (3.8) 13.9 o0.001 10.0 (4.6) 10.3 (4.5) 10.7 (4.4) 8.9 (4.5) 1.96 0.143 —
Race, white 204 (86.4) 83 0.66 0.414 68 (80.0) 20 (95.2) 36 (80.0) 58 (87.9) — 0.286 —
BMI 27.1 (5.6) 26.3 (3.3) 3.1 0.116 26.7 (5.3) 31.0 (6.3) 26.8 (6.1) 26.6 (5.3) 3.64 0.014 Bd4(Md= Sz=Ma)
Systemic disorder, yes 17 (7.2) — — — 11 (12.4) 0 2 (4.7) 4 (6.5) 5.03 0.169 —
Smokers, yes 62 (26.2) 18 2.2 0.104 25 (34.2) 8 (44.4) 14 (36.8) 15 (27.7) 1.94 0.583 —
Previous admissions, n 4.3 (4.2) — — — 2.64 (3.7) 3.2 (3.8) 4.3 (4.2) 7.3 (10.9) 6.36 o0.001 (Sz=Ma=Bd)4Md
Age of onset 29.4 (13.3) — — — 34.2 (13.6) 33.3 (10.8) 26.4 (14.7) 23.3 (9.4) 21.95 o0.001 (M= Sz)o (Md=Bd)
LOS, days 30.8 (21.4) — — — 25.3 (11.6) 30.9 (15.4) 32.0 (21.5) 37.7 (30.3) 8.44 0.005 (Ma= Bd= Sz)4Md
Treatment options during inpatient stay
Antidepressants, yes
Admission 78 (33.5) — — — 53 (48.2) 6 (28.6) 9 (20.9) 10 (16.1) 22.45 o0.001 Md= Bd4(Sz=Ma)
Discharge 89 (37.7) — — — 77 (71.3) 11 (52.4) 6 (14.0) 6 (9.7) 79.04 o0.001 (Md=BD)4(Sz=Ma)
Mood stabilizers, yes
Admission 80 (33.8) — — — 36 (32.7) 9 (42.9) 18 (41.9) 17 (27.4) 3.19 0.362 —
Discharge 79 (33.9) — — — 32 (31.4) 14 (66.7) 33 (76.7) 16 (25.8) 38.03 o0.001 (Ma=Bd)4(Md= Sz)
Antipsychotics, yes
Admission 141 (59.7) — — — 59 (53.6) 13 (61.9) 26 (60.5) 43 (69.4) 4.13 0.247 —
Discharge 199 (84.3) — — — 82 (74.5) 17 (81.0) 39 (90.7) 61 (98.4) 17.09 0.001 (Sz=Ma)4(Md=Bd)
ECT 68 (28.8) — — — 28 (31.8) 10 (47.6) 8 (18.6) 18 (29.0) 5.93 0.115 —
Abbreviations: BD, bipolar depression; BMI, body mass index; ECT, electroconvulsotherapy; F/X2, F statistics value/Χ2-statistics value; LOS, length of stay; Ma,
mania; Md, major depression; SMI, severe mental illness; Sz, schizophrenia. Values are shown as mean (s.d.) or n (%).
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Hedges’ g effect size (ES) was calculated based on differences between
the means.22 These controlled ESs were interpreted with Cohen’s
convention of small (0.2), medium (0.5) and large (0.8) effects.23
RESULTS
Sample characteristics
Sociodemographic and clinical characteristics and treatment
profiles of the total SMI patient sample, its diagnostic subgroups,
and controls are shown in Table 1. There were no significant
differences between diagnostic patient subgroups in years of study,
race, proportion of individuals with severe systemic disorders,
smoking status, global assessment of functioning at admission or
treatment with electroconvulsotherapy. However, there were
significant differences between subgroups in the mean age
(F:4.33; P=0.005), sex proportion (X2: 25.40; Po0.001), body mass
index (F= 3.64; P=0.014), number of previous psychiatric hospita-
lizations (F: 6.36; Po0.001), age of first episode (F:21.95; Po0.001),
hospitalization length (length of stay) (F: 8.44; P=0.005) and CGI-S
and Brief Psychiatric Rating Scale scores (F:5.30; P=0.012 and F:5.38;
P=0.001, respectively; Tables 1 and 2). Depressed patients were
older at their first episode, and had shorter length of stay and
significantly less previous psychiatric hospitalizations than other
subgroups. Schizophrenic patients had a greater proportion of male
individuals, a greater number of previous admissions and higher
CGI-S scores. Pharmacological treatment profiles also differed
between groups and are shown in Table 1. The total SMI patient
sample and all of the diagnostic subgroups showed significant
clinical and functional improvement during the inpatient treatment
(Table 2). CGI-S mean difference scores between admission and
discharge were 1.8 (t-test: 16.4; Po0.001) and showed a large ES
(ES: 1.72; 95% confidence interval (CI): 1.5, 1.95). For 74 SMI patients
(31.3%), BDNF data at discharge were missing.
When comparing the healthy controls and the SMI patients'
sample set (Table 1), the control group was found to be younger
(F: 17.07; Po0.001), and had a smaller proportion of female
individuals (X2 = 8.4; P= 0.004).
BDNF levels
The mean BDNF levels increased significantly during the inpatient
treatment when SMI patients were analyzed altogether
(Figure 1a). However, the ES of the difference between admission
and discharge was small (ES: − 0.22; 95% CI: − 0.43, 0.00). BDNF
levels showed significant reductions compared with controls both
at admission and upon discharge (Figure 1a). These reductions
indicate large to moderate ESs (ES: − 0.80; 95% CI: − 1.05, − 0.56
and ES: − 0.55; 95% CI: − 0.81, − 0.29, respectively). Age, sex,
weight and the presence of a severe general medical condition (in
SMI patients) did not significantly correlate with BDNF levels.
Table 2. Functional and clinical variables in admission and upon discharge
Variables SMI
n=236










Admission 34.1 (14.6) 34.5 (15.2) 40.0 (13.3) 34.7 (15.0) 31.2 (13.6) 1.98 0.118 —
Discharge 60.2 (16.7) 66.4 (12.8) 56.0 (19.2) 60.2 (18.1) 52.9 (16.7) 5.15 0.002 Szo (D= Bd=Ma)
BPRS
Admission 23.9 (10.8) 21.3 (9.8) 20.3 (7.4) 26.5 (11.2) 27.5 (11.7) 5.38 0.001 (Md=Bd=Ma)oSz
Discharge 9.6 (7.3) 7.8 (5.6) 11.1 (8.3) 7.7 (6.1) 12.9 (8.4) 5.48 0.001 (Md=Bd=Ma)oSz
CGI-S score
Admission 5.3 (0.97) 5.1 (1.00) 5.1 (0.8) 5.5 (0.87) 5.5 (0.95) 5.30 0.012 (Ma= Bd=Md)oSz
Discharge 3.4 (1.23) 3.0 (0.94) 3.4 (1.14) 3.3 (1.52) 4.1 (1.15) 6.55 o0.001 (Md=Bd=Ma)oSz
Abbreviations: BD, bipolar depression; BPRS, Brief Psychiatric Rating Scale; CGI-S, Clinical Global Impression Severity Scale; F, F statistics value; GAF, Global
Assessment of Functioning; Ma, mania; Md, major depression; SMI, severe mental illness; Sz, schizophrenia.
Figure 1. The mean BDNF serum levels in (a) SMI patient total
sample in admission and upon discharge and in healthy controls
and (b) in SMI patients subdivided by diagnosis in admission and
upon discharge. (a) In admission time point, SMI patients’ BDNF
serum level has a large difference when compared with controls (ES:
− 0.80; 95% CI: − 1.05, − 0.56). It increases during the inpatient
treatment and remains moderately reduced at discharge when
compared with controls (ES: − 0.55; 95% CI: − 0.81, − 0.29). (b) BDNF
levels among diagnoses are similar in both moments of the
treatment. BDNF, brain-derived neurotrophic factor; Bd, bipolar
depression; CI, confidence interval; ES, effect size; Ma, mania; Md,
major depression; SMI, severe mental illness; Sz, schizophrenia.
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In addition, BDNF levels were not significantly different
between SMI patients from different diagnostic subgroups at
both time points of the treatment (Figure 1b). Estimated serum
BDNF means (s.d.) at admission and upon discharge were 48.1
(24.5) and 51.3(22.6) in major depression; 45.4 (17.7) and 48.4
(20.0) in bipolar depression; 42.5 (20.7) and 53.1 (25.1) in manic
episode; and 46.5 (21.8) and 49.1 (19.0) in schizophrenia (Table 3).
Age, sex, weight and length of stay were not statistically
significantly correlated with BDNF levels in the GEE model.
Pharmacological interventions were not included in the analysis
because the sample was composed predominantly of patients
with combinations of multiple treatments. Furthermore, the use of
mood stabilizers and antipsychotics showed correlation, indicating
collinearity. Treatment with electroconvulsotherapy during the
hospitalization was evaluated in the first GEE analysis. However,
electroconvulsotherapy did not significantly correlate with BDNF
levels and was not included in the model.
DISCUSSION
The three main findings of this study are as follows: (1) SMI patient
serum BDNF levels significantly increase during inpatient treat-
ment and increased levels are associated with clinical improve-
ment; (2) estimated mean BDNF levels show no difference among
SMI patients with major depression, bipolar depression, manic
episode and schizophrenia; and (3) BDNF levels persist at a lower
level compared with controls even with the general improvement
of clinical scores during the inpatient treatment.
In this naturalistic study, we believe we are the first to replicate
in single samples obtained from 336 individuals (236 SMI patients
in an inpatient setting and 100 controls) the findings of one
previous meta-analysis,11 which showed that peripheral BDNF
levels were equally reduced in acute presentations among
different diagnoses. Furthermore, our results indicate a similar
reduction in BDNF levels in acute presentations.
Other meta-analyses of studies of individual disorders have
shown significantly reduced peripheral BDNF levels in major
psychiatric disorders. A meta-analysis of BDNF levels in major
depression showed that BDNF levels were substantially lower
when comparing healthy controls with antidepressant-treated
depressed patients.6 Similarly, serum BDNF levels were signifi-
cantly lower than in healthy controls in other studies that assessed
BDNF levels in depressive episodes.6 Furthermore, another meta-
analysis that studied manic episodes showed that BDNF levels in
manic patients were significantly lower than in controls.8 In
addition, in schizophrenia, a meta-analysis showed that peripheral
serum and plasma BDNF levels are moderately reduced when
compared with controls.9
Nevertheless, the increase in BDNF levels during treatment is
not so pronounced in our total sample. The lack of change in
BDNF subgroups was probably due to BDNF unspecificity among
different diagnoses and sample size effects. BDNF levels increase
but the non-restoration may reflect the characteristic disorder
progression observed in SMI patients.24 These findings support
the suggested role of BDNF in neuroprogression, a phenomenon
whereby the central nervous system pathologically reorganizes
during the course of a SMI.25,26 The SMI concept brings about a
link with disease-staging models, where the SMI patients show a
middle-to-late stage of an underlying disease process. In these
stages, patients usually have a poor outcome, with heavy medical
comorbidity, treatment-refractory symptoms and severely
impaired functioning. 24 Thus, SMI patients represent an end
stage or final phenotype of the psychiatric disorders.
Further studies are necessary to determine BDNF levels over
time. The SMI definition is based on the disorder duration, that is,
contact with services for 2 years or more. Interestingly, a 2-year
longitudinal study showed a more profound decrease in serum
BDNF levels in patients with persistent and remitted depression
than in non-depressed controls.27
The limitations of our findings should be addressed. First, there
were differences in some variables between controls and SMI
patients. However, these variables showed no significant con-
tribution to the analysis. Second, some data were missing, and this
is why GEEs were chosen. Third, BDNF was measured within a
short interval of time and we could not assure the stability of the
changes. Fourth, correlations between baseline and follow-up
BDNF levels were low, indicating a high between-subjects
variability of change in serum BDNF over time. Unfortunately,
the poor reproducibility of BDNF measures has to date prevented
its validation for clinical purposes.28 Last, pharmacological
treatments were not included in the analysis as most patients
used multiple combinations of different pharmacological inter-
ventions. Furthermore, recent evidence shows that medication
use does not affect BDNF serum levels as much as initially
thought.9
CONCLUSION
The similar reduction observed in BDNF levels among SMI patients
with different diagnoses and the significant increase but non-
restoration during inpatient treatment indicate that BDNF serum
levels could be considered a marker for the presence of an
unspecific psychiatric disorder and possibly a transdiagnostic and
unspecific marker of disease activity.
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Table 3. Serum BDNF in admission and upon discharge among diagnostic subgroups
SMI subgroup BDNF (pg ml− 1) Wald X2 P ES P
Admission Discharge
Major depression 48.1 (24.5) 51.3 (22.6) 0.887 0.357 0.13 0.418
Bipolar depression 45.4 (17.7) 48.4 (20.0) 0.382 0.536 0.16 0.592
Mania 42.5 (20.7) 53.1 (25.1) 3.464 0.063 0.44 0.084
Schizophrenia 46.5 (21.8) 49.1 (19.0) 0.641 0.423 0.12 0.544
Abbreviations: BDNF, brain-derived neurotrophic factor; ES, effect size; SMI, severe mental illness.
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